A single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type 1 diabetes: announced (with or without bolus reduction) vs unannounced exercise strategies.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
11 2020
Historique:
received: 14 04 2020
accepted: 15 06 2020
pubmed: 3 8 2020
medline: 3 11 2021
entrez: 3 8 2020
Statut: ppublish

Résumé

For individuals living with type 1 diabetes, closed-loop insulin delivery improves glycaemic control. Nonetheless, maintenance of glycaemic control during exercise while a prandial insulin bolus remains active is a challenge even to closed-loop systems. We investigated the effect of exercise announcement on the efficacy of a closed-loop system, to reduce hypoglycaemia during postprandial exercise. A single-blind randomised, crossover open-label trial was carried out to compare three strategies applied to a closed-loop system at mealtime in preparation for exercise taken 90 min after eating at a research testing centre: (1) announced exercise to the closed-loop system (increases target glucose levels) in addition to a 33% reduction in meal bolus (A-RB); (2) announced exercise to the closed-loop system and a full meal bolus (A-FB); (3) unannounced exercise and a full meal bolus (U-FB). Participants performed 60 min of exercise at 60% [Formula: see text] 90 min after eating breakfast. The investigators were not blinded to the interventions. However, the participants were blinded to the sensor glucose readings and to the insulin infusion rates throughout the intervention visits. The trial was completed by 37 adults with type 1 diabetes, all using insulin pumps: mean±SD, 40.0 ± 15.0 years of age, HbA Combining postprandial exercise announcement, which increases closed-loop system glucose target levels, with a 33% meal bolus reduction significantly reduced time spent in hypoglycaemia compared with the other two strategies, yet at the expense of more time spent in hyperglycaemia. ClinicalTrials.gov NCT0285530 FUNDING: JDRF (2-SRA-2016-210-A-N), the Canadian Institutes of Health Research (354024) and the Fondation J.-A. DeSève chair held by RR-L.

Identifiants

pubmed: 32740723
doi: 10.1007/s00125-020-05244-y
pii: 10.1007/s00125-020-05244-y
doi:

Substances chimiques

Blood Glucose 0

Banques de données

ClinicalTrials.gov
['NCT02855307']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2282-2291

Subventions

Organisme : CIHR
ID : 354024
Pays : Canada
Organisme : Juvenile Diabetes Research Foundation Canada
ID : 2-SRA-2016-210-A-N
Pays : International

Auteurs

Sémah Tagougui (S)

Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.
Department of Nutrition, Université de Montréal, Montreal, QC, Canada.
Université de Lille, Université d'Artois, Université du Littoral Côte d'Opale, ULR 7369 - URePSSS - Unité de Recherche Pluridisciplinaire Sport, Santé, Société (URePSSS), Lille, France.

Nadine Taleb (N)

Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.
Department of Biomedical Sciences, Université de Montréal, Montréal, QC, Canada.

Laurent Legault (L)

Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.
Montreal Children's Hospital, McGill University Health Centre (MUHC), Montreal, QC, Canada.

Corinne Suppère (C)

Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.

Virginie Messier (V)

Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.

Inès Boukabous (I)

Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada.

Azadeh Shohoudi (A)

Montreal Heart Institute, Montreal, QC, Canada.

Martin Ladouceur (M)

École de Santé Publique de l'Université de Montréal, Montreal, QC, Canada.

Rémi Rabasa-Lhoret (R)

Montreal Clinical Research Institute (IRCM), 110 Pine Ave W, Montreal, QC, H2W 1R7, Canada. remi.rabasa-lhoret@ircm.qc.ca.
Department of Nutrition, Université de Montréal, Montreal, QC, Canada. remi.rabasa-lhoret@ircm.qc.ca.
Montreal Diabetes Research Center, Montreal, QC, Canada. remi.rabasa-lhoret@ircm.qc.ca.
Endocrinology Division, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada. remi.rabasa-lhoret@ircm.qc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH